• Jason S Vourlekis, Marvin I Schwarz, Reuben M Cherniack, Douglas Curran-Everett, Carlyne D Cool, Rubin M Tuder, Talmadge E King, and Kevin K Brown.
• Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
• Am. J. Med. 2004 May 15;116(10):662-8.

PurposeTo determine the effect of pulmonary fibrosis on survival in an unselected group of patients with hypersensitivity pneumonitis.MethodsWe identified 72 patients with hypersensitivity pneumonitis confirmed by surgical lung biopsy in the database of the Clinical Interstitial Lung Disease Program at the National Jewish Medical and Research Center. All biopsy specimens were scored according to the presence or absence of fibrosis. Comparisons were made between patients with (fibrotic group) and without (nonfibrotic group) pathologic fibrosis. Vital status was ascertained and Kaplan-Meier curves were plotted. Cox regression analysis was used to determine predictors of survival.ResultsForty-six patients were classified as fibrotic and 26 as nonfibrotic. Twenty-nine percent had exposure to a bird antigen, 33% had exposure to a microbial antigen, and 38% had unknown exposure. Patients with fibrosis were significantly older, showed greater restrictive lung physiology, and had greater all-cause and respiratory mortality. Median survival in fibrotic patients was 7.1 years, which was significantly less than survival in those without fibrosis. In an age-adjusted regression analysis, antigen class, symptom duration, and lung function had no effect on survival. Only the presence of pathologic fibrosis was predictive of increased mortality (hazard ratio = 6.01; 95% confidence interval: 1.68 to 21.45; P = 0.006).ConclusionPulmonary fibrosis is associated with diminished survival in patients with hypersensitivity pneumonitis.

17 keywords...

hide…